Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sonnet Biotherapeutics Holdings Inc SONN

Consumer Cyclical Biotechnology
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. Its technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. It designed the FHAB construct to improve drug accumulation in tumors, and to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12, covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical stage asset, SON-080, is the native human version of IL-6 that is manufactured in Chinese Hamster Ovary cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy and Diabetic Peripheral Neuropathy. Its pipeline also includes SON-1210, SON-1410 and SON-3015.


NDAQ:SONN - Post by User

Sonnet Biotherapeutics Holdings Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(67)
•••
Post by Iseneschalon Nov 06, 2024 8:34am
19 Views
Post# 36298403

SONN....Kabooooom....huge news and rip

SONN....Kabooooom....huge news and rip

 

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

 

2024-11-06 05:30 ET - News Release

 

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 binding protein (IL-18BP)

IL-18 has significant importance for cancer immune-oncology and combination with IL-12 on Sonnet’s FHAB platform which Sonnet believes could present an important oncology possibility

The lock-and-load flexibility of the FHAB platform offers the bifunctional payload capability of adding another synergistic biologics target to IL-18 generating multiple novel cancer drugs

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities